Tuccatin™ 150 Tablets Tuccatin™ 150 Tablets contain Tucatinib, a selective HER2 tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine to treat HER2-positive unresectable or metastatic breast cancer. It works by blocking HER2 signaling, helping slow or stop the growth of cancer cells, including in patients with brain metastases.

Effects & Benefits Targets HER2-positive cancer cells to slow tumor growth. Used for HER2-positive metastatic or unresectable breast cancer. Effective in combination with trastuzumab and capecitabine. Demonstrates activity in patients with brain metastases. Helps improve progression-free survival. Oral tablet for convenient long-term treatment under specialist supervision.